TACE PATIENT SELECTION
BCLC AND CHILD-PUGH
TACE candidacy in HCC is determined by two frameworks working in parallel: the BCLC staging system that maps tumour burden to treatment strategy, and the Child-Pugh score that quantifies liver functional reserve. Understanding both helps patients assess their eligibility and engage meaningfully with their treatment team.
analyticsAt a Glance
- check_circleTACE is the BCLC-recommended treatment for BCLC B (intermediate stage): multinodular HCC without vascular invasion or extrahepatic spread
- check_circleChild-Pugh A (score 5–6) and B7 are the liver function thresholds for TACE eligibility — Child-Pugh C is a contraindication
- check_circlePerformance status must be ECOG 0–1 — poor performance status patients may not tolerate TACE-related toxicity
- check_circleBorderline or complex patients should be reviewed at a specialist hepatobiliary MDT — TACE eligibility is not always binary
Why Patient Selection Is the Most Important TACE Decision
TACE works by inducing intentional liver injury within the tumour's blood supply — a procedure that healthy liver parenchyma can survive because of its dual blood supply and regenerative capacity. In severely decompensated cirrhosis, this same process can trigger acute liver failure. Selecting patients whose liver function can withstand the procedure-related ischaemia is as important as selecting patients whose tumour burden makes TACE technically feasible.
“TACE in the wrong patient does not just fail to help — it can accelerate liver failure. The selection criteria are not bureaucratic gatekeeping; they represent the line between benefit and harm.”
The BCLC System: Staging That Guides Treatment
The Barcelona Clinic Liver Cancer (BCLC) system is the most widely used HCC staging framework globally — and uniquely links stage to recommended treatment. It integrates tumour size and number, vascular invasion, extrahepatic spread, liver function (Child-Pugh), and performance status into a single treatment algorithm. BCLC B specifically identifies the intermediate-stage population for whom TACE has the most evidence.
Child-Pugh Score: Measuring Liver Reserve
The Child-Pugh score quantifies liver functional reserve by scoring five clinical and laboratory parameters (bilirubin, albumin, prothrombin time, ascites, encephalopathy) on a scale of 5–15. Child-Pugh A (5–6) indicates well-compensated liver function; B (7–9) indicates moderate decompensation; C (10–15) indicates severe decompensation. TACE is generally appropriate for Child-Pugh A and B7 — higher scores carry prohibitive risk.
BCLC Staging System: All Stages and Their Treatment Implications
Understanding where your HCC sits on the BCLC staging ladder explains why your oncologist has recommended a specific treatment — and whether TACE is the appropriate modality for your stage.
| BCLC Stage | Definition | Liver Function | Performance Status | First-Line Treatment |
|---|---|---|---|---|
| 0 — Very Early | Single nodule ≤2 cm | Child-Pugh A | ECOG 0 | Resection or ablation (RFA/microwave) — curative intent |
| A — Early | Single nodule any size, or up to 3 nodules all ≤3 cm, no vascular invasion, no extrahepatic spread | Child-Pugh A–B | ECOG 0 | Resection, liver transplant (if within Milan), or ablation — curative intent |
| B — Intermediate | Multinodular — beyond Milan criteria, no vascular invasion, no extrahepatic spread | Child-Pugh A–B | ECOG 0 | TACE — standard first-line; Y-90 radioembolisation alternative at selected centres |
| C — Advanced | Any tumour with vascular invasion (portal vein thrombosis) OR extrahepatic spread (lymph nodes, metastases) | Child-Pugh A–B | ECOG 1–2 | Systemic therapy — sorafenib/lenvatinib first-line; atezolizumab + bevacizumab if eligible |
| D — Terminal | Any tumour with severe liver decompensation OR very poor performance status | Child-Pugh C | ECOG 3–4 | Best supportive care — no anti-tumour treatment appropriate; palliation focus |
Child-Pugh Score: How It Is Calculated
The Child-Pugh score assigns 1–3 points to each of five parameters — the total score (5–15) determines the class (A, B, or C) and TACE eligibility.
| Parameter | 1 Point (Normal) | 2 Points (Abnormal) | 3 Points (Severely Abnormal) |
|---|---|---|---|
| Total bilirubin | <34 µmol/L (<2 mg/dL) | 34–51 µmol/L (2–3 mg/dL) | >51 µmol/L (>3 mg/dL) |
| Serum albumin | >35 g/L | 28–35 g/L | <28 g/L |
| Prothrombin time (INR) | <1.7 (PT prolonged <4 sec) | 1.7–2.3 (PT 4–6 sec) | >2.3 (PT >6 sec) |
| Ascites | Absent | Mild (controlled with diuretics) | Moderate/severe (refractory) |
| Hepatic encephalopathy | None | Grade I–II (or suppressed with medication) | Grade III–IV (refractory) |
TACE Eligibility Criteria: What Must Be Assessed Before Proceeding
The following criteria must all be considered before TACE is offered — a specialist liver cancer MDT review is the appropriate setting for this assessment.
| Criterion | Supports TACE Eligibility | Relative or Absolute Contraindication |
|---|---|---|
| BCLC Stage | BCLC B (intermediate): standard; BCLC A if ablation not possible; bridge to transplant for BCLC A within Milan | BCLC C (vascular invasion or extrahepatic spread) — systemic therapy preferred; BCLC D — supportive care only |
| Child-Pugh Score | A (5–6): optimal; B7: acceptable with careful patient selection | B8–9: high risk — individualised decision; C (10–15): absolute contraindication |
| Portal vein status | Patent portal vein: standard TACE appropriate | Main portal vein tumour thrombus: relative-absolute contraindication (perfusion to normal liver dependent on portal flow) |
| Tumour volume | Tumour occupying <50% of liver volume | >50% liver involvement: very high risk of hepatic decompensation post-TACE |
| Biliary anatomy | Normal biliary drainage | Biliary obstruction (risk of cholangitis/biloma); prior biliary intervention — increased biliary complication risk |
| Extrahepatic disease | No extrahepatic spread | Extrahepatic metastases: TACE alone will not address systemic disease; systemic therapy should accompany or replace TACE |
| Performance status | ECOG 0–1 | ECOG 2+: reduced physiological reserve to tolerate post-embolisation syndrome |
| Renal function | Creatinine <150 µmol/L; GFR >40 mL/min | Significant renal impairment: contrast nephropathy risk; IV hydration and minimised contrast required |
| Coagulation | INR <1.5; platelet count >50,000/µL | Uncorrected coagulopathy: bleeding risk at femoral access site |
TACE Eligibility: Key Reference Numbers
The thresholds most commonly used in clinical practice for TACE eligibility assessment.
- B7Maximum Child-Pugh score for TACE eligibilityChild-Pugh B7 is the accepted upper boundary for TACE in most expert centres — B8 and above carries unacceptably high risk of post-TACE liver decompensation.
- BCLC BThe primary TACE-indicated stage in the BCLC systemBCLC B (intermediate stage: multinodular, no vascular invasion, no extrahepatic spread) is the population in which TACE has Level 1 evidence for survival benefit.
- 50%Maximum liver tumour volume for safe TACETumours occupying >50% of liver volume leave insufficient functional parenchyma to survive TACE-induced ischaemia — an important radiological threshold.
- 30–40%Of BCLC B patients are reassessed as BCLC C or ineligible at specialist MDT reviewSpecialist multidisciplinary team review changes the staging or eligibility assessment in a substantial proportion of patients initially referred for TACE — highlighting the importance of expert evaluation.
More from the TACE Resource Library
Continue exploring TACE — from technique selection to survival data and transplant bridge applications.
- What Is TACE? A Patient Introduction to Liver Cancer Embolisation
- cTACE vs DEB-TACE: Which Technique Is Right for Your HCC?
- TACE Survival Data: Evidence from Pivotal Clinical Trials
- TACE as Bridge to Liver Transplant: How It Works
- TACE Therapy — Complete Treatment Guide
- Cryoablation for Liver Tumours: HCC and Metastases
Frequently Asked Questions
Common questions about TACE staging and eligibility.
About BCLC and Child-Pugh
I have a Child-Pugh B score of 8 — does this mean I cannot have TACE?
Child-Pugh B8 is in the borderline-to-contraindicated range for TACE, and most guidelines recommend against TACE at this level of decompensation. However, the decision is not always binary at B8 — it depends on which components drive the score (ascites vs encephalopathy vs bilirubin), whether they are reversible with treatment, and the tumour-specific clinical urgency. If ascites can be controlled with diuretics and albumin infusion, improving the Child-Pugh from B8 to B7, TACE may become feasible. This assessment requires review at a specialist hepatobiliary MDT that includes both a hepatologist and an interventional radiologist. CancerFax can facilitate this specialist review of your specific situation.
My BCLC stage was classified as B by my local team but C by the oncologist at a different hospital — which is correct?
BCLC staging requires careful assessment of portal vein status, extrahepatic disease, and performance status — all of which can be interpreted differently depending on imaging quality, radiologist expertise, and clinical context. Portal vein tumour thrombus in particular can be present on some MRI sequences and not on CT, or may be ambiguous (bland vs tumour thrombus). The classification matters because BCLC B → TACE vs BCLC C → systemic therapy is a fundamentally different treatment pathway. If you have received discordant staging, request review at a specialist liver cancer MDT where hepatobiliary surgeons, oncologists, radiologists, and interventional radiologists review all cases together — this is the setting where staging discordances are most reliably resolved.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Not Sure If You Are Eligible for TACE?
CancerFax reviews your imaging, Child-Pugh score, BCLC staging, and portal vein status to provide a specialist eligibility assessment — and connects you with interventional radiologists and hepatologists who make these decisions daily at high-volume liver cancer programmes.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.